17403-47-3

Basic information

• Product Name: 5-Nitro-2,3-dihydro-1-benzofuran
• Synonyms: 5-Nitro-2,3-dihydro-1-benzofuran;5-Nitro-2,3-dihydrobenzofuran;2,3-Dihydro-5-nitrobenzofuran
• CAS NO: 17403-47-3
• Molecular Formula: C₈H₇NO₃
• Molecular Weight: 165.14608
• Mol File: 17403-47-3.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 292.3±29.0 °C(Predicted)
• Appearance: /
• Density: 1.360±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 5-Nitro-2,3-dihydro-1-benzofuran(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Nitro-2,3-dihydro-1-benzofuran(17403-47-3)
• EPA Substance Registry System: 5-Nitro-2,3-dihydro-1-benzofuran(17403-47-3)

Safety Data

• Hazardous Substances Data: 17403-47-3(Hazardous Substances Data)

Usage

General Description

5-Nitro-2,3-dihydro-1-benzofuran is a nitro compound with the molecular formula C8H7NO4. It is a yellow crystalline solid that is insoluble in water but soluble in organic solvents. This chemical is used in the pharmaceutical industry for the synthesis of various drugs and is also a precursor in the production of agricultural chemicals. It is important to handle 5-Nitro-2,3-dihydro-1-benzofuran with caution as it is toxic and may cause skin and eye irritation upon contact. Additionally, this compound is considered to be harmful if swallowed or inhaled and should be stored and handled in a well-ventilated area with appropriate protective equipment.

Upstream product

• 496-16-2 2.3-dihydrobenzofuran 
• 7169-34-8 3-oxo-2,3-dihydrobenzo[b]furan 

Downstream Products

• 42933-43-7 2,3-dihydro-1-benzofuran-5-amine 
• 84594-78-5 6-nitro-2,3-dihydro-1-benzofuran-5-ylamine 
• 1228880-71-4 5,6-diamino-2,3-dihydrobenzofuran 
• 911300-51-1 6-nitro-2,3-dihydro-1-benzofuran 
• 57786-34-2 6-amino-2,3-dihydrobenzofuran 
• 245762-35-0 5-fluoro-2,3-dihydrobenzofuran 

Relevant articles and documents

Discovery of dual-acting opioid ligand and TRPV1 antagonists as novel therapeutic agents for pain

In order to discover a novel type of analgesic, we investigated dual activity ligands with TRPV1 antagonism and mu-opioid receptor affinity with the goal of eliciting synergistic analgesia while avoiding the side effects associated with single targeting.

Structure-activity relationship of human glutaminyl cyclase inhibitors having an N-(5-methyl-1H-imidazol-1-yl)propyl thiourea template

In an effort to design inhibitors of human glutaminyl cyclase (QC), we have synthesized a library of N-aryl N-(5-methyl-1H-imidazol-1-yl)propyl thioureas and investigated the contribution of the aryl region of these compounds to their structure-activity relationships as cyclase inhibitors. Our design was guided by the proposed binding mode of the preferred substrate for the cyclase. In this series, compound 52 was identified as the most potent QC inhibitor with an IC50 value of 58 nM, which was two-fold more potent than the previously reported lead 2. Compound 52 is a most promising candidate for future evaluation to monitor its ability to reduce the formation of pGlu-Aβ and Aβ plaques in cells and transgenic animals.

Design, structure-activity relationship, and highly efficient asymmetric synthesis of 3-phenyl-4-benzylaminopiperidine derivatives as novel neurokinin-1 receptor antagonists

We synthesized a series of novel 3-phenyl-4-benzylaminopiperidine derivatives that were identified as potent tachykinin NK1 receptor antagonists by structural modification of the 3-benzhydrylpiperidone derivative through high-throughput screening. N-{2-[(3R,4S)-4-({2-Methoxy-5-[5-(trifluoromethyl)- 1Htetrazol-1-yl]benzyl}amino)-3-phenyl-1-piperidinyl]-2-oxoethyl}acetamide ((+)-39) was found to be one of the most potent tachykinin NK1 receptor antagonists with high metabolic stability. Highly efficient asymmetric synthesis of (+)-39 was achieved via dynamic kinetic resolution.